I'm LongbridgeAI, I can summarize articles.YABAO PHARM.CORP signed a technology transfer agreement for a traditional Chinese medicine new drug project with the Shanxi Provincial Academy of Traditional Chinese Medicine, acquiring the clinical trial approval, patent rights, and related technical materials for the Class 1.1 new drug "Chaiqin Ning Shen Granules," with a transaction amount of 22 million yuan. This move will help the company accelerate the R&D progress of innovative traditional Chinese medicines and enhance its core competitiveness, but it will have little impact on operating performance in the short term
According to the Zhitong Finance APP, YABAO PHARM.CORP (600351.SH) announced that on August 4, 2025, it signed a traditional Chinese medicine new drug project technology transfer agreement with the Shanxi Provincial Academy of Traditional Chinese Medicine (referred to as "Shanxi Provincial Hospital of Traditional Chinese Medicine"). The company acquired the clinical trial approval, patent rights, and related technical materials for the traditional Chinese medicine Class 1.1 new drug "Chaiqin Ning Shen Granules" from Shanxi Provincial Hospital of Traditional Chinese Medicine for RMB 22 million.
The acquisition of the clinical trial approval and invention patent for the innovative traditional Chinese medicine Chaiqin Ning Shen Granules will help the company rapidly expand its research and development pipeline for innovative traditional Chinese medicines, accelerate the development progress of new products, and enhance the company's core competitiveness and sustainable development capabilities, aligning with the company's development strategy and the interests of all shareholders. After the signing of this agreement, due to the long timeline for the advancement of various matters, there is uncertainty, and it will not have a significant impact on the company's operating performance in the short term